Adding carboplatin to standard neoadjuvant chemotherapy improved outcomes in younger patients with triple-negative breast cancer.
All articles by Lauren Dembeck, PhD
Combination cemiplimab, REGN3767, and chemotherapy appears effective in triple-negative breast cancer and HR+, HER2- breast cancer.
Ribociclib plus endocrine therapy prolongs progression-free survival when compared with chemotherapy in HR+/ HER2− advanced breast cancer.
A retrospective study revealed characteristics of patients with metastatic breast cancer who are not likely to receive first-line systemic therapy.
Continuing CDK4/6 inhibitor therapy and switching ET after disease progression does not improve progression-free survival vs switching ET alone in HR+, HER2- metastatic breast cancer.
Adding capivasertib to treatment with fulvestrant improved progression-free survival in aromatase inhibitor-resistant, HR+, HER2- advanced breast cancer.
Adding abemaciclib to adjuvant endocrine therapy can provide long-term benefits for patients with high-risk, HR+, HER2- early breast cancer, updated data suggest.
Adding everolimus to adjuvant endocrine therapy does not improve survival for patients with HR+, HER2- breast cancer.
Latest News Your top articles for MondayFor More Personalized News
Haymarket Medical NetworkTop Picks
Continuing Medical Education (CME/CE) Courses